M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal Article
Identification, Synthesis, and Biological Evaluation of the Major Human Metabolite of NLRP3 Inflammasome Inhibitor MCC950
Manohar Salla,Mark S. Butler,Ruby Pelingon,Geraldine Kaeslin,Daniel E. Croker,Janet C. Reid,Jong Min Baek,Paul V. Bernhardt,Elizabeth M. J. Gillam,Mark E. Cooper,Avril A. B. Robertson +10 more
TL;DR: The identified metabolite 2a was 170-fold less potent than MCC950, while one regioisomer had nanomolar inhibitory activity, and gives first insight into the SAR of the hexahydroindacene moiety.
Journal ArticleDOI
Lipids and diabetic renal disease
TL;DR: Clinical studies have in general been underpowered, but a recent meta-analysis and findings from the Heart Protection Study suggest that statins may be renoprotective, and with the convincing antiatherosclerotic effects of these agents, they should be widely administered in the diabetic population with or at risk for nephropathy.
Journal ArticleDOI
Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin
TL;DR: Dalbavancin, a semi-synthetic glycopeptide with enhanced antibiotic activity compared to vancomycin and teicoplanin, dimerises strongly in an anti-cooperative manner with ligand binding.
Journal ArticleDOI
Kinetic analysis of high-mobility-group proteins HMG-1 and HMG-I/Y binding to cholesterol-tagged DNA on a supported lipid monolayer
TL;DR: High-mobility-group proteins H MG-1 and HMG-I/Y bind to multiple sites within a 268 bp A/T-rich enhancer element of the pea plastocyanin gene ( PetE ) but should bind preferentially at the overlapping binding site within this region of the PetE enhancer.
Journal ArticleDOI
Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs
Andrew V. Stachulski,Karl A.D. Swift,Mark E. Cooper,Stephen J. Reynolds,Daniel Norton,Steven D. Slonecker,Jean-Francois Rossignol +6 more
TL;DR: In order to improve their systemic absorption, new amino-ester prodrug derivatives of 1b and RM4848 2b were prepared and tested for their animal pharmacology, pharmacokinetics and toxicology, and showed a good safety profile in animal safety pharmacology and Toxicology.